Wang Yin-xiang
2009
Citations
2
Influential Citations
14
Citations
Quality indicators
Journal
Chinese Journal of New Drugs
Abstract
Icotinib hydrochloride is a novel oral epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).It is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with one or two chemotherapy.Several phase I and IIa trials in both healthy volunteers and NSCLC patients have been conducted in China recently.In this review we summarized the brief results from these trials,the pharmacology and pharmacokinetics of icotinib hydrochloride.